CN1620433A - 作为内皮肽转化酶抑制剂的吡咯烷衍生物 - Google Patents

作为内皮肽转化酶抑制剂的吡咯烷衍生物 Download PDF

Info

Publication number
CN1620433A
CN1620433A CNA018130232A CN01813023A CN1620433A CN 1620433 A CN1620433 A CN 1620433A CN A018130232 A CNA018130232 A CN A018130232A CN 01813023 A CN01813023 A CN 01813023A CN 1620433 A CN1620433 A CN 1620433A
Authority
CN
China
Prior art keywords
alkyl
methyl
pyrrolidine
naphthalene
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA018130232A
Other languages
English (en)
Chinese (zh)
Inventor
约翰尼斯·埃必
丹尼丝·布卢姆
丹尼尔·布尔
亚历山大·丘乔楼斯凯
亨丽埃格·德姆洛
埃里克·阿尔吉里奥斯·基塔斯
贝恩德·米夏埃尔·勒夫勒
乌尔丽克·奥布斯特
扎比内·瓦尔鲍姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1620433A publication Critical patent/CN1620433A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
CNA018130232A 2000-07-19 2001-07-10 作为内皮肽转化酶抑制剂的吡咯烷衍生物 Pending CN1620433A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00114947 2000-07-19
EP00114947.5 2000-07-19

Publications (1)

Publication Number Publication Date
CN1620433A true CN1620433A (zh) 2005-05-25

Family

ID=8169224

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA018130232A Pending CN1620433A (zh) 2000-07-19 2001-07-10 作为内皮肽转化酶抑制剂的吡咯烷衍生物

Country Status (16)

Country Link
US (1) US6541638B2 (enExample)
EP (1) EP1303485A1 (enExample)
JP (1) JP4068452B2 (enExample)
KR (1) KR100568841B1 (enExample)
CN (1) CN1620433A (enExample)
AR (1) AR033984A1 (enExample)
AU (1) AU2001270627A1 (enExample)
BR (1) BR0112580A (enExample)
CA (1) CA2414311C (enExample)
GT (1) GT200100145A (enExample)
MX (1) MXPA03000223A (enExample)
PA (1) PA8522501A1 (enExample)
PE (1) PE20020294A1 (enExample)
UY (1) UY26847A1 (enExample)
WO (1) WO2002006222A1 (enExample)
ZA (1) ZA200300167B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110078593A (zh) * 2018-11-15 2019-08-02 南通正达农化有限公司 一种苹果蠹蛾性信息素的合成方法
CN119661387A (zh) * 2024-12-18 2025-03-21 长沙普济生物科技股份有限公司 一种烷基胺与3-卤代丙酸酯合成N-烷基-β-氨基丙酸钠的方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000368A (es) * 2000-07-19 2004-09-13 Hoffmann La Roche Derivados de pirrolidina como inhibidores de metalproteasa.
TWI312779B (enExample) * 2000-12-28 2009-08-01 Daiichi Seiyaku Co
DE60336986D1 (de) 2002-03-05 2011-06-16 Sumitomo Chemical Co Verfahren zur herstellung von biarylverbindungen
EP1613269B1 (en) 2003-04-04 2015-02-25 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
AU2004231070B2 (en) 2003-04-10 2008-02-14 Amgen, Inc. Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof
CA2522084A1 (en) 2003-04-10 2004-10-28 Amgen Inc. Cyclic amine derivatives and their use in the treatment of inflammation-related disorders mediated by bradykinin
MXPA05013469A (es) 2003-06-20 2006-03-09 Amgen Inc Derivados de piperazina y metodos de uso.
MXPA06000850A (es) 2003-07-24 2006-03-30 Daiichi Seiyaku Co Compuesto de acido ciclohexancarboxilico.
CN1294120C (zh) * 2003-10-21 2007-01-10 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其应用
US20100022568A1 (en) * 2006-04-13 2010-01-28 Actelion Pharmaceeuticals Ltd. Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
ES2350548B1 (es) * 2009-06-25 2011-09-29 Institut Univ. De Ciència I Tecnologia, S.A. N-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica.
EP2730571A1 (en) * 2012-11-12 2014-05-14 Universitat De Barcelona 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
WO2019009317A1 (ja) * 2017-07-05 2019-01-10 日産化学株式会社 ベンジル化合物
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1283906C (en) * 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
AU644008B2 (en) * 1990-08-10 1993-12-02 Sumitomo Pharmaceuticals Company, Limited Beta-lactam compounds, and their production and use
JP3091297B2 (ja) * 1992-01-10 2000-09-25 住友製薬株式会社 ピロリジン誘導体およびその製造方法
BR9712792A (pt) * 1996-08-28 1999-12-14 Procter & Gamble Inibidores de metaloprotease bidentada.
DE69716449T2 (de) * 1996-08-28 2003-08-07 The Procter & Gamble Company, Cincinnati Substituierte zyklische amine als metalloproteaseinhibitoren
CA2294341C (en) * 1997-07-10 2007-09-25 Merck & Co., Inc. Crystalline forms of antibiotic side chain intermediates
YU66700A (sh) * 1998-05-01 2003-01-31 Kyoto Pharmaceutical Industries Ltd. Derivati karbapenema, njihovo korišćenje i intermedijarna jedinjenja istih

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110078593A (zh) * 2018-11-15 2019-08-02 南通正达农化有限公司 一种苹果蠹蛾性信息素的合成方法
CN119661387A (zh) * 2024-12-18 2025-03-21 长沙普济生物科技股份有限公司 一种烷基胺与3-卤代丙酸酯合成N-烷基-β-氨基丙酸钠的方法
CN119661387B (zh) * 2024-12-18 2025-12-16 长沙普济生物科技股份有限公司 一种烷基胺与3-卤代丙酸酯合成N-烷基-β-氨基丙酸钠的方法

Also Published As

Publication number Publication date
AR033984A1 (es) 2004-01-21
AU2001270627A1 (en) 2002-01-30
ZA200300167B (en) 2004-04-07
BR0112580A (pt) 2003-06-17
JP2004504297A (ja) 2004-02-12
UY26847A1 (es) 2002-01-31
GT200100145A (es) 2002-05-16
CA2414311C (en) 2008-01-08
PA8522501A1 (es) 2002-09-17
KR100568841B1 (ko) 2006-04-10
PE20020294A1 (es) 2002-04-17
US6541638B2 (en) 2003-04-01
US20020049243A1 (en) 2002-04-25
JP4068452B2 (ja) 2008-03-26
CA2414311A1 (en) 2002-01-24
MXPA03000223A (es) 2003-06-06
WO2002006222A1 (en) 2002-01-24
KR20030016416A (ko) 2003-02-26
EP1303485A1 (en) 2003-04-23

Similar Documents

Publication Publication Date Title
CN1620433A (zh) 作为内皮肽转化酶抑制剂的吡咯烷衍生物
CN1171870C (zh) 半胱氨酸蛋白酶抑制剂
CN1186322C (zh) 脯氨酸衍生物及其医药用途
CN1087736C (zh) 新型的脒基萘基衍生物或其盐
CN1723196A (zh) 作为二肽酶抑制剂的氟代吡咯烷
CN1863797A (zh) 具有苯甲酰胺取代基的环胺bace－1抑制剂
CN1649864A (zh) 丝氨酸蛋白酶、特别是丙型肝炎病毒ns3－ns4蛋白酶的抑制剂
CN1265675A (zh) 抑制由vla－4介导的白细胞粘着的苄基化合物
CN1894274A (zh) 丙肝病毒ns3丝氨酸蛋白酶的大环抑制剂
CN1863770A (zh) 具有杂环取代基的环胺base－1抑制剂
CN1599724A (zh) 咪唑－4－羧酰胺衍生物及其制备和用于治疗肥胖症的方法
CN1795188A (zh) 丝氨酸蛋白酶、特别是hcv ns3－ns4a蛋白酶的抑制剂
CN1960990A (zh) 作为用于治疗或预防糖尿病的二肽基肽酶－ⅳ抑制剂的环己基丙氨酸衍生物
CN1362954A (zh) 氨基磺酸基异羟肟酸金属蛋白酶抑制剂
CN1655780A (zh) 用作前列腺素受体调节剂的噻唑烷甲酰胺衍生物
CN1703221A (zh) 作为黑皮质素受体配体用于治疗肥胖症的2－烷基－(2－氨基－3－芳基－丙酰基)哌嗪衍生物及相关化合物
CN1146765A (zh) 咪唑衍生物在治疗与血管紧张肽at1及at2受体有关疾病方面的应用，某些这样的化合物，它们的制法，它们作为医药的应用以及含有它们的药物组合物
CN1384100A (zh) 苯并－1,3－间二氧杂环戊烯基和苯并呋喃基取代的吡咯烷衍生物
CN1950357A (zh) 用作tafia抑制剂的咪唑衍生物
CN1256324C (zh) 用作Xa因子抑制剂的吡咯烷衍生物
CN1360577A (zh) 作为基质金属蛋白酶抑制剂的异羟肟酸衍生物
CN1656071A (zh) 新哌啶化合物
CN1151148C (zh) 具有吡咯结构的法尼转移酶抑制剂及其制备方法
CN1675180A (zh) 吲哚、吲唑和氮茚衍生物
CN1443164A (zh) 作为金属蛋白酶抑制剂的吡咯烷衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication